US, European Covid vaccine developers make pledge to uphold testing rigour | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Saturday
June 14, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
SATURDAY, JUNE 14, 2025
US, European Covid vaccine developers make pledge to uphold testing rigour

Coronavirus chronicle

Reuters
08 September, 2020, 04:35 pm
Last modified: 08 September, 2020, 04:40 pm

Related News

  • Lost angels: How the West is turning against the very immigrants who helped build it
  • Marines prepare for Los Angeles deployment as protests spread across US
  • Deal to get US-China trade truce back on track is done, Trump says
  • China's mega-embassy faces its MAGA nemesis
  • US cities brace for more protests as parts of Los Angeles placed under curfew

US, European Covid vaccine developers make pledge to uphold testing rigour

The companies, including Pfizer, GlaxoSmithKline and AstraZeneca, in a joint statement made a "historic pledge... to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first Covid-19 vaccines"

Reuters
08 September, 2020, 04:35 pm
Last modified: 08 September, 2020, 04:40 pm
File Photo: Small bottles labeled with a "Vaccine Covid-19" sticker and a medical syringe are seen in this illustration taken April 10, 2020. Reuters/Dado Ruvic/Illustration/File Photo
File Photo: Small bottles labeled with a "Vaccine Covid-19" sticker and a medical syringe are seen in this illustration taken April 10, 2020. Reuters/Dado Ruvic/Illustration/File Photo

Nine leading US and European vaccine developers pledged on Tuesday to uphold the scientific standards that their experimental immunisations will be held against, amid a hurried global race to contain the pandemic.

The companies, including Pfizer, GlaxoSmithKline and AstraZeneca, in a joint statement made a "historic pledge... to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first Covid-19 vaccines".

The unusual move to promise to play by well-established rules underlines a highly politicised debate over what action is needed to quickly rein in the spread of the deadly disease and to jumpstart global business and trade.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

The head of the US Food and Drug Administration (FDA) said last month that the normal approval process may be bypassed for a Covid-19 vaccine as long as officials were convinced the benefits outweigh the risks, prompting a call for caution from the World Health Organisation.

Developers globally have yet to produce large-scale trial data showing actual infections in participants, yet Russia granted approval to a Covid-19 vaccine last month, prompting some Western experts to criticize a lack of testing.

The head of China's Sinovac Biotech said most of its employees and their families have already taken an experimental vaccine developed by the Chinese firm under the country's emergency-use programme.

"We want it to be known that also in the current situation we are not willing to compromise safety and efficacy," said co-signatory Ugur Sahin, the chief executive of Pfizer's German partner BioNTech.

"Apart from the pressure and the hope for a vaccine to be available as fast as possible, there is also a lot of uncertainty among people that some development steps may be omitted here," he added.

BioNTech and Pfizer have raised the prospect of unveiling pivotal trial data in October, potentially placing it at the centre of bitter US presidential politics ahead of the Nov. 3 election.

According to the statement, the nine companies pledge to follow established guidance from expert regulatory authorities such as the FDA.

Among other hurdles, approval must be based on large, diverse clinical trials with comparative groups that do not receive the vaccine in question. Participants and those working on the trial must not know which group they belong to, according to the pledge.

BioNTech's Sahin added there must be statistical certainty of 95 percent, in some cases higher, that a positive reading on efficacy does not just come from random variations but reflects the underlying workings of the compound.

The list of co-signatories is completed by Johnson & Johnson , Merck & Co, Moderna, Novavax and Sanofi.

Sahin said inclusion in the pledge broadly reflected a significant vaccines market share or a leading position in coronavirus vaccine development.

The frenetic development race has intensified safety concerns about an inoculation, polls have shown.

Western regulators have stressed they would not cut corners but rather prioritise the review workload and allow for development steps in parallel that would normally be handled consecutively.

covid-19 vaccine / US / Europe / Pfizer / AstraZeneca Covid-19 Vaccine / GlaxoSmithKline

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Missiles launched from Iran are intercepted as seen from Tel Aviv. REUTERS/Jamal Awad
    Iran fires missiles at Israel in response to attacks; Trump says it's not too late for nuclear deal
  • Logo of National Citizen Party (NCP)
    People won't accept election date before July Charter is implemented: NCP on Yunus-Tarique meeting
  • Yunus-Tarique meeting: Jamaat says outcome positive for democracy, IAB says dispelled uncertainty from politics
    Yunus-Tarique meeting: Jamaat says outcome positive for democracy, IAB says dispelled uncertainty from politics

MOST VIEWED

  • Wreckage of a Boeing 787 Dreamliner showing part of its registration "VT-ANB" in Ahmedabad, India, June 12, 2025. REUTERS/Amit Dave
    Air India Dreamliner crashes into Ahmedabad college hostel, kills over 290
  • File Photo of Chief Adviser Muhammad Yunus: UNB
    Prof Yunus to receive Harmony Award from King Charles today
  • Energy adviser Fouzul Kabir Khan with other government officials during a visit to Sylhet gas field on 13 June 2025. Photo: TBS
    I would disconnect gas supply to every home in Dhaka if I could: Energy adviser
  • Bangladesh Bank Governor Ahsan H Mansur. TBS Sketch
    Bangladesh mulls settlements with tycoons over offshore wealth: BB governor tells FT
  • UCB declares no dividend for 2024 to comply with regulatory requirement
    UCB declares no dividend for 2024 to comply with regulatory requirement
  • UK Prime Minister Keir Starmer, Chief Adviser Muhammad Yunus
    Disclosure of unconfirmed Yunus-Starmer meeting shows ‘diplomatic imprudence’: Analysts

Related News

  • Lost angels: How the West is turning against the very immigrants who helped build it
  • Marines prepare for Los Angeles deployment as protests spread across US
  • Deal to get US-China trade truce back on track is done, Trump says
  • China's mega-embassy faces its MAGA nemesis
  • US cities brace for more protests as parts of Los Angeles placed under curfew

Features

Photos: Collected

Kurtis that make a great office wear

11h | Mode
Among pet birds in the country, lovebirds are the most common, and they are also the most numerous in the haat. Photo: Junayet Rashel

Where feathers meet fortune: How a small pigeon stall became Dhaka’s premiere bird market

2d | Panorama
Illustration: Duniya Jahan/ TBS

Forget Katy Perry, here’s Bangladesh’s Ruthba Yasmin shooting for the moon

3d | Features
File photo of Eid holidaymakers returning to the capital from their country homes/Rajib Dhar

Dhaka: The city we never want to return to, but always do

4d | Features

More Videos from TBS

No Cash in ATMs: System Glitch or Something Deeper?

No Cash in ATMs: System Glitch or Something Deeper?

5h | TBS Today
Iran-Israel military power; who is ahead?

Iran-Israel military power; who is ahead?

7h | TBS World
Did the possibility of an Iran nuclear deal set back after the attack?

Did the possibility of an Iran nuclear deal set back after the attack?

8h | TBS World
IRGC chief Major General Hossein Salami killed in Israeli strike

IRGC chief Major General Hossein Salami killed in Israeli strike

10h | TBS World
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net